These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21343953)

  • 1. Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm G
    Nat Rev Endocrinol; 2011 Mar; 7(3):134-5. PubMed ID: 21343953
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
    J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling the role of denosumab in prostate cancer.
    Aragon-Ching JB
    Lancet; 2011 Mar; 377(9768):785-6. PubMed ID: 21353698
    [No Abstract]   [Full Text] [Related]  

  • 5. Denosumab an option for patients with bone metastasis from breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
    [No Abstract]   [Full Text] [Related]  

  • 6. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab for bone metastases from breast cancer: a new therapy option?
    Aapro MS
    J Clin Oncol; 2011 May; 29(14):e419-20; author reply e421-4. PubMed ID: 21464408
    [No Abstract]   [Full Text] [Related]  

  • 9. Future directions of bone-targeted therapy for metastatic breast cancer.
    Onishi T; Hayashi N; Theriault RL; Hortobagyi GN; Ueno NT
    Nat Rev Clin Oncol; 2010 Nov; 7(11):641-51. PubMed ID: 20808302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
    von Moos R; Body JJ; Egerdie B; Stopeck A; Brown JE; Damyanov D; Fallowfield LJ; Marx G; Cleeland CS; Patrick DL; Palazzo FG; Qian Y; Braun A; Chung K
    Support Care Cancer; 2013 Dec; 21(12):3497-507. PubMed ID: 23975226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
    Sorscher SM; Lockhart AC
    J Clin Oncol; 2011 Jul; 29(19):2735-6; author reply 2736-8. PubMed ID: 21646612
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone targeted therapy in breast cancer: present and future.
    Huober J; Thürlimann B
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
    [No Abstract]   [Full Text] [Related]  

  • 13. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.
    Jilani A; Garrett Z; Sutcliffe F; Stevens A
    Lancet Oncol; 2012 Dec; 13(12):1194-5. PubMed ID: 23323278
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
    Vadhan-Raj S; von Moos R; Fallowfield LJ; Patrick DL; Goldwasser F; Cleeland CS; Henry DH; Novello S; Hungria V; Qian Y; Feng A; Yeh H; Chung K
    Ann Oncol; 2012 Dec; 23(12):3045-3051. PubMed ID: 22851406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing metastases to bone: denosumab or bisphosphonates?
    Nanes MS
    J Bone Miner Res; 2010 Mar; 25(3):437-9. PubMed ID: 20200989
    [No Abstract]   [Full Text] [Related]  

  • 17. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
    Lipton A; Fizazi K; Stopeck AT; Henry DH; Brown JE; Yardley DA; Richardson GE; Siena S; Maroto P; Clemens M; Bilynskyy B; Charu V; Beuzeboc P; Rader M; Viniegra M; Saad F; Ke C; Braun A; Jun S
    Eur J Cancer; 2012 Nov; 48(16):3082-92. PubMed ID: 22975218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibition of RANK ligand to treat bone metastases].
    Body JJ
    Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman RE; Paterson AH; Gao GM; Kinsey AC; Peterson MC; Jun S
    Clin Cancer Res; 2008 Oct; 14(20):6690-6. PubMed ID: 18927312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
    Van Poznak CH; Temin S; Yee GC; Janjan NA; Barlow WE; Biermann JS; Bosserman LD; Geoghegan C; Hillner BE; Theriault RL; Zuckerman DS; Von Roenn JH;
    J Clin Oncol; 2011 Mar; 29(9):1221-7. PubMed ID: 21343561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.